Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07895394
PHASE4

Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients

Sponsor: Seoul National University Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.

Official title: Analysis of Vaccine-induced Immune Responses and Optimization of Protective Immunity Against Respiratory Syncytial Virus in Lung Transplant Recipients

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2026-10

Completion Date

2028-10

Last Updated

2026-10-26

Healthy Volunteers

No

Interventions

BIOLOGICAL

RSVPreF3 vaccination

One dose of RSVPreF3 (Arexvy®) vaccine

Locations (1)

Seoul National University Hospital

Seoul, Jongno-Gu, South Korea